Physician Groups React to Report on Pharma Payments to Providers
Specifically addressing formal medical education scenarios, Ralston told HealthLeaders that much of the onus resides on conference organizers to be alert to conflicts of interest and "develop and enforce explicit policies that maintain complete control of program planning, content and delivery."
"Backgrounds have not always been thoroughly vetted and hopefully this information will help those offering educational content develop processes to keep this from happening in the future," he said.
Noted in the study and accompanying article published by ProPublica is that payout findings only covered seven pharmaceutical companies—including giants AstraZeneca, Eli Lilly, Merck and Pfizer—that voluntarily made physician payment information public.
These relationships are expected to come under greater scrutiny as the more than 70 drug companies operating in the United States are forced to release physician payment information by March 2013 in accordance with healthcare reform mandates.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- Centralizing the Revenue Cycle Protects the Bottom Line
- IOM Identifies GME Problems, Calls for Finance Changes
- Revenue Cycles Get a Boost from Simple JPEG Files
- CA Fines 8 Hospitals for Medical Errors
- Healthcare Costs Start With What We Eat
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability